Clinical Trials Brief | March 30, 2026
This week's five signals cover a global real-world-safety standard moving into implementation, a new FDA push to validate alternatives to animal testing, a concrete CTIS modernization signal from EMA, a vaccine-related safety update from PRAC, and an AI-driven industry collaboration that shows where biomarker development is going next.
Real-world safety evidence is becoming more structured, not less
What changed
FDA listed final guidances for ICH M14 and ICH E2D(R1), covering use of real-world data in post-approval safety assessment and standards for individual case safety reporting.
Why it matters
Post-market safety evidence is becoming more method-driven and more harmonized across regulators, which affects sponsors, pharmacovigilance teams, and real-world-data strategy.
Takeaway
Real-world evidence is no longer a loose concept. Regulators increasingly expect fit-for-purpose data, disciplined study design, and clearer reporting standards.
FDA is pushing validation standards for alternatives to animal testing
What changed
FDA issued draft guidance intended to help developers validate new approach methodologies for use instead of animal testing in drug development.
Why it matters
The practical barrier to adoption is regulatory confidence, not interest. Validation standards are what make new methods operationally usable.
Takeaway
This is a measured shift toward human-relevant nonclinical evidence, not an overnight end to animal studies.
EMA is signaling that CTIS modernization is now part of the clinical-trials competitiveness story
What changed
EMA said CTIS improvements are planned for 2026, including a new safety module in June, and that the first KPI readout on trial attractiveness and speed will be published in April.
Why it matters
Europe is treating trial infrastructure and speed more explicitly as strategic issues, not just compliance tasks.
Takeaway
Watch the April KPI release and the June CTIS safety-module rollout as early indicators of whether CTIS is becoming a real performance tool.
PRAC updated the risk picture for Ixchiq after aseptic meningitis was reported in a healthy young adult
What changed
PRAC said serious side effects such as aseptic meningitis have also been observed in healthy young adults and recommended updating product information accordingly.
Why it matters
The key issue is not only that the risk exists, but that the population context around a known risk has broadened.
Takeaway
Good safety reading means watching how risk characterization changes, not just whether a warning exists at all.
Tempus and Merck are betting that multimodal AI can become a biomarker engine, not just an analytics layer
What changed
Tempus and Merck announced an expanded multi-year collaboration using Tempus' de-identified multimodal data and AI infrastructure to support biomarker discovery and oncology development.
Why it matters
This is a concrete example of AI moving toward narrower, development-relevant use cases rather than generic claims about AI in pharma.
Takeaway
The near-term AI story is less about replacing evidence generation and more about improving candidate, biomarker, and combination selection.